(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/182540 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/12* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2024/017731

(22) International Filing Date:
28 February 2024 (28.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/487,386 28 February 2023 (28.02.2023) US
63/494,604 06 April 2023 (06.04.2023) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PUTARJUNAN, Aarthi**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **STAHMER, Kyle**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BOUCHER, Lauren**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LI, Lianjie**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **DEERING, Raquel**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LIN, Chia-Yang**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **YANCOPOULOS, George**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HANSEN, Johanna**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **BRUNER, J. Kyle** et al.; BIOSPARK INTELLECTUAL PROPERTY LAW, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
06 February 2025 (06.02.2025)

WO 2024/182540 A3

(54) Title: MULTISPECIFIC MOLECULES COMPRISING A PEPTIDE-MHC COMPLEX COMPRISING AN MHC DOMAIN AND AN ANTIGENIC PEPTIDE AND AN IMMUNE CELL ANTIGEN TARGETING MOIETY

(57) Abstract: The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular aspects relate to multimeric (*e.g.*, dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of use of multispecific molecules in antigen-specific T cell activation, in inducing an antigen-specific immune response, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells that express the multispecific molecules, and methods of producing the multispecific molecules.